The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I, Eisele S, Remer I, Schmitz J, Zeschky K, Colberg C, Stachon P, Wolf D, Willecke F, Buchner M, Zirlik K, Ortiz-Rodriguez A, Lozhkin A, Hoppe N, von zur Muhlen C, zur Hausen A, Bode C, Zirlik A.
Hilgendorf I, et al. Among authors: bode c.
Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):1991-9. doi: 10.1161/ATVBAHA.111.230847. Epub 2011 Jun 23.
Arterioscler Thromb Vasc Biol. 2011.
PMID: 21700926